Literature DB >> 32819894

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions.

C Elliott1, D L Arnold2,3, H Chen4, C Ke4, L Zhu4, I Chang4, E Cahir-McFarland4, E Fisher4, B Zhu4, S Gheuens4, M Scaramozza4, V Beynon4, N Franchimont4, D P Bradley4, S Belachew4.   

Abstract

BACKGROUND AND
PURPOSE: Slowly expanding/evolving lesions measured by conventional T1-weighted/T2-weighted brain MR imaging may contribute to progressive disability accumulation in MS. We evaluated the longitudinal change in myelin and axonal tissue integrity in white matter slowly expanding/evolving lesions by means of the magnetization transfer ratio and DTI radial diffusivity.
MATERIALS AND METHODS: Slowly expanding/evolving lesions were detected within the Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY) Phase 2 clinical trial dataset (NCT01864148), comprising patients with relapsing-remitting and secondary-progressive MS (n = 299) with T1-weighted/T2-weighted MR imaging at all trial time points (baseline to week 72).
RESULTS: Compared with non-slowly expanding/evolving lesions (areas not classified as slowly expanding/evolving lesion) of baseline nonenhancing T2 lesions, slowly expanding/evolving lesions had a lower normalized magnetization transfer ratio and greater DTI radial diffusivity, both in patients with relapsing-remitting MS (n = 242) and secondary-progressive MS (n = 57, P < .001 for all). Although the changes with time in both the normalized magnetization transfer ratio and DTI radial diffusivity between slowly expanding/evolving lesions and non-slowly expanding/evolving lesions were positively correlated (P < .001), a decrease in the normalized magnetization transfer ratio and a greater increase in DTI radial diffusivity were observed in slowly expanding/evolving lesions versus non-slowly expanding/evolving lesions from baseline to week 72 in relapsing-remitting MS and secondary-progressive MS (P < .001 for all).
CONCLUSIONS: Patterns of longitudinal change in the normalized magnetization transfer ratio and DTI radial diffusivity in slowly expanding/evolving lesions were consistent with progressive demyelination and tissue loss, as seen in smoldering white matter MS plaques.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32819894      PMCID: PMC7583098          DOI: 10.3174/ajnr.A6742

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions.

Authors:  Martina Absinta; Pascal Sati; Matthew Schindler; Emily C Leibovitch; Joan Ohayon; Tianxia Wu; Alessandro Meani; Massimo Filippi; Steven Jacobson; Irene C M Cortese; Daniel S Reich
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

2.  Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Authors:  Diego Cadavid; Michelle Mellion; Raymond Hupperts; Keith R Edwards; Peter A Calabresi; Jelena Drulović; Gavin Giovannoni; Hans-Peter Hartung; Douglas L Arnold; Elizabeth Fisher; Richard Rudick; Sha Mi; Yi Chai; Jie Li; Yiwei Zhang; Wenting Cheng; Lei Xu; Bing Zhu; Susan M Green; Ih Chang; Aaron Deykin; Sarah I Sheikh
Journal:  Lancet Neurol       Date:  2019-07-05       Impact factor: 44.182

3.  Clinical feasibility of brain quantitative susceptibility mapping.

Authors:  Shun Zhang; Zhe Liu; Thanh D Nguyen; Yihao Yao; Kelly M Gillen; Pascal Spincemaille; Ilhami Kovanlikaya; Ajay Gupta; Yi Wang
Journal:  Magn Reson Imaging       Date:  2019-04-04       Impact factor: 2.546

Review 4.  Advanced MRI and staging of multiple sclerosis lesions.

Authors:  Martina Absinta; Pascal Sati; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-04-29       Impact factor: 42.937

5.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

Authors:  Frederik Barkhof; Wolfgang Bruck; Corline J A De Groot; Elisabeth Bergers; Sandra Hulshof; Jeroen Geurts; Chris H Polman; Paul van der Valk
Journal:  Arch Neurol       Date:  2003-08

6.  Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging.

Authors:  E Mark Haacke; Malek Makki; Yulin Ge; Megha Maheshwari; Vivek Sehgal; Jiani Hu; Madeswaran Selvan; Zhen Wu; Zahid Latif; Yang Xuan; Omar Khan; James Garbern; Robert I Grossman
Journal:  J Magn Reson Imaging       Date:  2009-03       Impact factor: 4.813

7.  Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions.

Authors:  Jacqueline T Chen; D Louis Collins; Harold L Atkins; Mark S Freedman; Douglas L Arnold
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

8.  Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.

Authors:  Colm Elliott; Jerry S Wolinsky; Stephen L Hauser; Ludwig Kappos; Frederik Barkhof; Corrado Bernasconi; Wei Wei; Shibeshih Belachew; Douglas L Arnold
Journal:  Mult Scler       Date:  2018-12-19       Impact factor: 6.312

9.  Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis.

Authors:  Kunio Nakamura; Nicolas Guizard; Vladimir S Fonov; Sridar Narayanan; D Louis Collins; Douglas L Arnold
Journal:  Neuroimage Clin       Date:  2013-10-29       Impact factor: 4.881

10.  The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.

Authors:  Joana Machado-Santos; Etsuji Saji; Anna R Tröscher; Manuela Paunovic; Roland Liblau; Galina Gabriely; Christian G Bien; Jan Bauer; Hans Lassmann
Journal:  Brain       Date:  2018-07-01       Impact factor: 15.255

View more
  5 in total

1.  Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.

Authors:  Vanessa Beynon; Ilena C George; Colm Elliott; Douglas L Arnold; Jun Ke; Huaihou Chen; Li Zhu; Chunlei Ke; Gavin Giovannoni; Matthew Scaramozza; Nolan Campbell; Daniel P Bradley; Nathalie Franchimont; Arie Gafson; Shibeshih Belachew
Journal:  BMJ Neurol Open       Date:  2022-06-07

2.  Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study.

Authors:  A Dal-Bianco; R Schranzer; G Grabner; M Lanzinger; S Kolbrink; G Pusswald; P Altmann; M Ponleitner; M Weber; B Kornek; K Zebenholzer; C Schmied; T Berger; H Lassmann; S Trattnig; S Hametner; F Leutmezer; P Rommer
Journal:  Front Neurol       Date:  2021-12-21       Impact factor: 4.003

3.  Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.

Authors:  Shannon Kolind; Shawna Abel; Carolyn Taylor; Roger Tam; Cornelia Laule; David K B Li; Hideki Garren; Laura Gaetano; Corrado Bernasconi; David Clayton; Irene Vavasour; Anthony Traboulsee
Journal:  Neuroimage Clin       Date:  2022-07-19       Impact factor: 4.891

Review 4.  Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.

Authors:  Malgorzata Siger
Journal:  Clin Neuroradiol       Date:  2022-03-08       Impact factor: 3.156

5.  Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy.

Authors:  Samuel Klistorner; Michael H Barnett; John Parratt; Con Yiannikas; Stuart L Graham; Alexander Klistorner
Journal:  Ann Clin Transl Neurol       Date:  2022-09-03       Impact factor: 5.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.